SPIE Digital Library Get updates from SPIE Newsroom
  • Newsroom Home
  • Astronomy
  • Biomedical Optics & Medical Imaging
  • Defense & Security
  • Electronic Imaging & Signal Processing
  • Illumination & Displays
  • Lasers & Sources
  • Micro/Nano Lithography
  • Nanotechnology
  • Optical Design & Engineering
  • Optoelectronics & Communications
  • Remote Sensing
  • Sensing & Measurement
  • Solar & Alternative Energy
  • Sign up for Newsroom E-Alerts
  • Information for:
SPIE Defense + Commercial Sensing 2017 | Register Today

OPIE 2017

OPIC 2017




Print PageEmail Page

Biomedical Optics & Medical Imaging

Tumor paint

Blaze Bioscience

Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, will present the company's first Tumor Paint product, BLZ-100, at SPIE Photonics West 2016 in San Francisco, 13-18 February.  

BLZ-100 is the first Tumor Paint product candidate being developed for cancer surgery in multiple solid tumor types. BLZ-100 is a drug administered by IV injection that circulates within the body and "lights up" cancer cells. It consists of an optide, which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range.

Preclinical utility of BLZ-100 has been demonstrated in a wide range of cancer types, including brain, breast, prostate, lung, colorectal, skin, and sarcomas. BLZ-100 is currently in multiple Phase 1 clinical trials.